However, panels involving those markers could be considered for non-invasive screening in high-risk populations such as patients with strong familial history of breast/ovarian cancer and with BRCA1 or BRCA2 (breast cancer gene 1 and 2, respectively) mutations where early and more accurate OC detection would facilitate the determination of the optimal time for preventive surgery. The gene discussed is BRCA2; the disease is breast carcinoma.